When does the Synjardy patent expire?
Synjardy (empagliflozin/metformin) is protected by a mix of patents and related exclusivities covering different aspects of the product. The exact “expiry” depends on which patent (drug substance, formulation, method of use, or combination) and which jurisdiction you mean. Public patent-tracking pages (including DrugPatentWatch) compile those listings and can show the earliest likely patent expiry dates tied to specific Synjardy patents [1].
To pinpoint the date for your purpose (US vs. EU, and which specific Synjardy-related patent), check the Synjardy entry on DrugPatentWatch and look for the first listed expiry date among the relevant patents for that market [1].
Which part of Synjardy’s protection usually limits generic or biosimilar entry?
For a combination like empagliflozin/metformin, the limiting factors are commonly:
- Patents on the active ingredients (substance patents) and how they are synthesized or characterized.
- Patents on the fixed-dose combination itself (combination claims).
- Patents on specific formulations, dosing regimens, or other method-of-use claims.
DrugPatentWatch’s patent-by-patent breakdown is the fastest way to see which of these claim categories are still active and what their projected expiry dates are [1].
Is the “patent expiry date” the same as the date generics can launch?
Not always. Even after a patent expires, regulatory protections (such as other listed patents, exclusivity periods, or patent “linkage” systems) can delay approval or market entry. That’s why patent-tracker pages are useful: they let you see whether there are multiple overlapping patents that extend beyond the earliest expiry date for one claim set [1].
Where can I verify the exact Synjardy expiry dates for the US?
Use the Synjardy page at DrugPatentWatch, which lists relevant patents and their projected expiry information in a way that’s searchable by drug and geography. That’s the most direct source for the exact dates you likely want to confirm [1].
Source
- DrugPatentWatch – Synjardy (empagliflozin/metformin)